Lee Kevin C, Pascal Alexander B, Halepas Steven, Koch Alia
Resident, Division of Oral and Maxillofacial Surgery, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY.
Dental Student, Division of Oral and Maxillofacial Surgery, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY.
J Oral Maxillofac Surg. 2020 Jul;78(7):1190.e1-1190.e9. doi: 10.1016/j.joms.2020.02.016. Epub 2020 Feb 21.
The purpose of the present study was to determine the most commonly reported complications with cosmetic botulinum toxin type A (BTX-A) treatments.
The present study was a cross-sectional review of the US Food and Drug Administration (FDA) Adverse Event Reporting System. From January 2014 through September 2019, records were included in the study sample if they implicated Botox (onabotulinumtoxinA), Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), or Jeuveau (prabotulinumtoxinA-xvfs), and if the indication for use had been to perform a cosmetic skin procedure. The study predictors included patient (ie, age, weight, gender) and treatment (ie, product, country of treatment, 10 most common reactions) characteristics. The study outcome was the frequency of serious events as defined by the standard FDA definition for biologic products. A multivariate logistical regression model was created for the study outcome using all significant univariate predictors.
The final sample included 10,577 reports detailing 29,471 adverse events and covering 1,473 reactions. The mean patient age was 48.4 ± 11.2 years, and nearly all patients were women (95.0%). The most commonly reported events were pain (9.3%), swelling (6.4%), and eyelid/brow ptosis (6.1%). Serious outcomes occurred in 13.5% of patients. In the multivariate model, serious outcomes were independently associated with older age, heavier weight, headache, allergy, vision changes, fatigue, facial paresis, and dizziness but notably were not associated with pain, swelling, or ptosis.
A wide range of alleged complications have been reported to the FDA, many of which were likely not mediated through injection or direct toxin effects. Patients may have inaccurately attributed some of their symptoms to BTX-A, and providers should be prepared to dispel any misinformation. Local complications such as pain, swelling, and ptosis were the most common reactions but were not associated with serious patient outcomes. However, constitutional symptoms should be approached more carefully.
本研究的目的是确定A型肉毒毒素(BTX-A)美容治疗中最常报告的并发症。
本研究是对美国食品药品监督管理局(FDA)不良事件报告系统的横断面回顾。从2014年1月至2019年9月,如果记录涉及保妥适(onabotulinumtoxinA)、Dysport(abobotulinumtoxinA)、Xeomin(incobotulinumtoxinA)或吉适(prabotulinumtoxinA-xvfs),且使用指征为进行美容皮肤手术,则将其纳入研究样本。研究预测因素包括患者(即年龄、体重、性别)和治疗(即产品、治疗国家、10种最常见反应)特征。研究结果是FDA对生物制品的标准定义所界定的严重事件的发生率。使用所有显著的单变量预测因素为研究结果创建了一个多变量逻辑回归模型。
最终样本包括10577份报告,详细记录了29471起不良事件,涵盖1473种反应。患者的平均年龄为48.4±11.2岁,几乎所有患者为女性(95.0%)。最常报告的事件是疼痛(9.3%)、肿胀(6.4%)和眼睑/眉毛下垂(6.1%)。13.5%的患者出现严重后果。在多变量模型中,严重后果与年龄较大、体重较重、头痛、过敏、视力变化、疲劳、面部麻痹和头晕独立相关,但值得注意的是,与疼痛、肿胀或下垂无关。
FDA已收到大量所谓并发症的报告,其中许多可能并非由注射或毒素直接作用介导。患者可能将一些症状错误地归因于BTX-A,医疗服务提供者应准备好消除任何错误信息。疼痛、肿胀和下垂等局部并发症是最常见的反应,但与严重的患者后果无关。然而,对于全身性症状应更谨慎对待。